EndoRobotics, a South Korean company focused on flexible endoscopic surgical robots, announced that its ROBOPERA system technology has been officially designated as a National Core Technology (NCT) by the Ministry of Trade, Industry and Energy. The company said the decision follows a formal review under South Korea's industrial technology protection framework. According to EndoRobotics, the recognition confirms that its surgical robotics platform carries strategic value that warrants state-level protection.
National Core Technology Designation Confirmed
South Korea's National Core Technology program identifies technologies with high economic value and growth potential whose overseas transfer could seriously affect national security or economic development. The designation is managed under the Act on Prevention of Divulgence and Protection of Industrial Technology. EndoRobotics stated that its core endoscopic surgical robot technologies are now formally recognized as strategic assets requiring national-level protection and management.
The ROBOPERA system was classified under the category covering design, manufacturing, and control technology for laparoscopic, endoscopic, and image-guided surgical robot systems. EndoRobotics explained that this moves its accumulated intellectual property beyond the status of an individual corporate asset. The company added that the classification reflects the broader strategic importance of its technology portfolio within South Korea's advanced medical robotics sector.
ROBOPERA Platform and Regulatory Milestones
ROBOPERA is designed to insert robotic instruments through natural openings such as the mouth or anus alongside an endoscope. The platform supports the removal of lesions in digestive organs, including the stomach and large intestine, without external incisions. It has already received 510(k) clearance from the United States Food and Drug Administration, marking an important regulatory milestone.
EndoRobotics described itself as a globally oriented surgical robotics company rather than a domestic-only medical device provider. Following the designation, the company said it will strictly implement legally mandated protective measures while continuing to strengthen its research and development capabilities. It also plans to upgrade its technology security systems in line with national requirements.
Global Commercial Strategy and Leadership Outlook
In May, EndoRobotics signed a global exclusive distribution partnership with Olympus, a major medical technology company. The company is now accelerating final preparations for its planned launch in the United States market during the second half of the year. With the new designation expected to enhance external confidence in its technology, EndoRobotics intends to use its US launch as a foundation for broader global expansion.
Co-CEO Byung Gon Kim said the National Core Technology determination officially confirms that EndoRobotics has built an important technology area requiring national protection and management. He added that the designation serves as a milestone demonstrating the strategic importance and trustworthiness of the company's technology assets as it cooperates and competes globally. Kim also stated that EndoRobotics will create a leading example of South Korean surgical robot technology succeeding in the global market.
Strategic Validation and Market Potential
The company views the designation as a validation of both its technical capability and its readiness to compete with established global players. It also strengthens EndoRobotics' position in discussions with international partners and healthcare providers ahead of commercialization. The announcement comes at a time when demand for minimally invasive surgical options continues to grow across major markets.
With FDA clearance, an exclusive Olympus partnership, and National Core Technology designation, EndoRobotics has assembled a notable combination of regulatory, commercial, and strategic credentials. The company is positioning ROBOPERA to address unmet needs in incisionless endoscopic surgery while expanding from South Korea into global markets. Its progress illustrates how domestic medical robotics innovation can gain institutional validation and pursue international commercialization at the same time.